Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eledon Pharmaceuticals, Inc. - Common Stock (NQ:ELDN)

2.620 +0.110 (+4.38%)
Streaming Delayed Price Updated: 4:00 PM EST, Mar 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,057,209
Open 2.540
Bid (Size) 2.660 (5,800)
Ask (Size) 2.700 (1,100)
Prev. Close 2.510
Today's Range 2.520 - 2.720
52wk Range 1.350 - 4.600
Shares Outstanding 22,506,956
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
+61.7%
+61.7%
1 Month
+18.6%
+18.6%
3 Month
+64.8%
+64.8%
6 Month
+0.4%
+0.4%
1 Year
-33.5%
-33.5%

More News

Read More
News headline image
Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Tuesday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Via Benzinga
News headline image
Eledon Pharmaceuticals Stock Plunges Following $50 Million Public Offering
Via MarketMinute
Topics Initial Public Offering Intellectual Property Regulatory Compliance
News headline image
Top movers in Wednesday's pre-market session ↗
Via Chartmill
News headline image
Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals (ELDN) Plummets Nearly 50% Amidst Mixed Phase 2 Trial Results, Sparking Investor Concern
Via MarketMinute
News headline image
What's going on in today's after hours session ↗
Via Chartmill
News headline image
What's going on in today's session ↗
Via Chartmill
News headline image
Eledon Pharmaceuticals' Lead Asset Fails In Mid-Stage Study, But Pushes Forward With Pivotal Study ↗
Via Benzinga
News headline image
Dow Dips Over 200 Points; Fluor Shares Slide After Q3 Results ↗
Via Benzinga
Topics Stocks
News headline image
Keep an eye on the top gainers and losers in Friday's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Via Benzinga
News headline image
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Discover the top movers in Friday's pre-market session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Via Benzinga
News headline image
Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology’s Kidney Week 2025 Annual Meeting
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Eledon Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Eledon Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Eledon Pharmaceuticals, Inc. - Common Stock trade on?
Eledon Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Eledon Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Eledon Pharmaceuticals, Inc. - Common Stock is ELDN on the Nasdaq Stock Market
What is the current price of Eledon Pharmaceuticals, Inc. - Common Stock?
The current price of Eledon Pharmaceuticals, Inc. - Common Stock is 2.620
When was Eledon Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Eledon Pharmaceuticals, Inc. - Common Stock was at 03/05/26 04:00 PM ET
What is the market capitalization of Eledon Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Eledon Pharmaceuticals, Inc. - Common Stock is 58.97M
How many shares of Eledon Pharmaceuticals, Inc. - Common Stock are outstanding?
Eledon Pharmaceuticals, Inc. - Common Stock has 59M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.